サマリー

市場の展望
Triton Market Researchのレポートによると、アジア太平洋地域のセルライト治療市場は、2023年から2030年にかけてCAGR9.83%で成長すると予測されています。本レポートでは、中国、日本、インド、韓国、オーストラリア・ニュージーランド、ASEAN諸国、その他のアジア太平洋地域を含む、この地域の複数の国にわたる市場を評価しています。
中国には熟練した形成外科医が多数存在し、彼らの存在が市場の成長促進に重要な役割を果たすと期待されています。中国の美容・パーソナルケア製品産業は、世界最大級の規模を誇っています。この点で、高級な美容製品やサービスに対する需要の高まりは、業界の成長をさらに強めています。したがって、美容分野の拡大がセルライト治療市場にチャンスをもたらしています。
日本は、世界的に見ても美容整形手術の件数が最も多く、際立っています。日本ではアンチエイジング、ブライトニング、保湿製品の需要が依然として高く、その結果、化粧品・パーソナルケア産業は拡大しています。このほか、技術の進歩や医療観光の増加により、セルライト除去を含むさまざまな美容施術の需要が急増しています。これはセルライト治療市場の発展をさらに加速させます。

競争展望
セルライト治療市場の注目すべき企業は、Bausch Health Companies Inc、Cutera Inc、Galderma SA、Endo International Plc、Sientra Inc.で構成されています。

ページTOPに戻る

目次

TABLE OF CONTENTS
1. ASIA-PACIFIC CELLULITE TREATMENT MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. PARENT MARKET ANALYSIS
2.2. IMPACT ANALYSIS ON THE CELLULITE TREATMENT MARKET
2.2.1. COVID-19 IMPACT ON THE CELLULITE TREATMENT MARKET
2.2.2. UKRAINE-RUSSIA WAR IMPACT ON THE CELLULITE TREATMENT MARKET
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. MARKET MATURITY ANALYSIS
2.5. INDUSTRY COMPONENTS
2.5.1. RESEARCH AND DEVELOPMENT
2.5.2. MANUFACTURING OF PRODUCT
2.5.3. DISTRIBUTION
2.5.4. POST-SALES MONITORING
2.6. REGULATORY FRAMEWORK
2.7. KEY BUYING IMPACT ANALYSIS
2.7.1. PRICE
2.7.2. BRAND NAME
2.7.3. USABILITY
2.8. KEY MARKET STRATEGIES
2.8.1. COLLABORATIONS
2.8.2. PRODUCT LAUNCHES
2.8.3. MERGERS & ACQUISITIONS
2.8.4. BUSINESS DIVESTITURES & EXPANSIONS
2.9. MARKET DRIVERS
2.9.1. GROWING PREVALENCE OF OBESITY
2.9.2. RAPIDLY GROWING MEDICAL TOURISM SECTOR
2.9.3. RISING DEMAND FOR AESTHETIC PROCEDURES
2.10. MARKET CHALLENGES
2.10.1. LACK OF KNOWLEDGE REGARDING CELLULITE TREATMENT
2.10.2. HIGH PRICE OF ADVANCED CELLULITE TREATMENT
2.10.3. RISKS ASSOCIATED POST-TREATMENT
2.11. MARKET OPPORTUNITIES
2.11.1. RISING BEAUTY CONSCIOUSNESS
2.11.2. INCREASING TREND OF ANTI-CELLULITE MASSAGE
2.11.3. GROWING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES
2.11.4. RISING POPULARITY OF RADIOFREQUENCY THERAPY FOR CELLULITE TREATMENT
2.11.5. ADVANCEMENTS IN TECHNOLOGIES AND NEW PRODUCT LAUNCHES
2.12. ANALYST PERSPECTIVE
3. ASIA-PACIFIC CELLULITE TREATMENT MARKET – BY CELLULITE TYPE
3.1. SOFT CELLULITE
3.2. HARD CELLULITE
3.3. EDEMATOUS CELLULITE
4. ASIA-PACIFIC CELLULITE TREATMENT MARKET – BY PROCEDURE TYPE
4.1. NON-INVASIVE
4.2. MINIMALLY INVASIVE
4.3. TOPICAL
5. ASIA-PACIFIC CELLULITE TREATMENT MARKET – BY END-USER
5.1. HOSPITALS
5.2. CLINICS AND BEAUTY CENTERS
5.3. OTHER END-USERS
6. ASIA-PACIFIC CELLULITE TREATMENT MARKET – BY COUNTRY OUTLOOK
6.1. COUNTRY ANALYSIS
6.1.1. CHINA
6.1.1.1. CHINA CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.2. JAPAN
6.1.2.1. JAPAN CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.3. INDIA
6.1.3.1. INDIA CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.4. SOUTH KOREA
6.1.4.1. SOUTH KOREA CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.5. ASEAN COUNTRIES
6.1.5.1. ASEAN COUNTRIES CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.6. AUSTRALIA & NEW ZEALAND
6.1.6.1. AUSTRALIA & NEW ZEALAND CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.7. REST OF ASIA-PACIFIC
6.1.7.1. REST OF ASIA-PACIFIC CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
7. COMPETITIVE LANDSCAPE
7.1. JOHNSON & JOHNSON
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY STRENGTHS
7.1.4. KEY CHALLENGES
7.2. ABBVIE INC
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY STRENGTHS
7.2.4. KEY CHALLENGES
7.3. BAUSCH HEALTH COMPANIES INC
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY STRENGTHS
7.3.4. KEY CHALLENGES
7.4. CUTERA INC
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY STRENGTHS
7.4.4. KEY CHALLENGES
7.5. INCELER MEDIKAL
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY STRENGTHS
7.5.4. KEY CHALLENGES
7.6. ZIMMER MEDIZINSYSTEME GMBH
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY STRENGTHS
7.6.4. KEY CHALLENGES
7.7. GALDERMA SA
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY STRENGTHS
7.7.4. KEY CHALLENGES
7.8. SIENTRA INC
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY STRENGTHS
7.8.4. KEY CHALLENGES
7.9. ENDO INTERNATIONAL PLC
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY STRENGTHS
7.9.4. KEY CHALLENGES
7.10. CANDELA MEDICAL CORPORATION
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY STRENGTHS
7.10.4. KEY CHALLENGES
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.1.1. OBJECTIVES OF STUDY
8.1.2. SCOPE OF STUDY
8.2. SOURCES OF DATA
8.2.1. PRIMARY DATA SOURCES
8.2.2. SECONDARY DATA SOURCES
8.3. RESEARCH METHODOLOGY
8.3.1. EVALUATION OF THE PROPOSED MARKET
8.3.2. IDENTIFICATION OF DATA SOURCES
8.3.3. ASSESSMENT OF MARKET DETERMINANTS
8.3.4. DATA COLLECTION
8.3.5. DATA VALIDATION & ANALYSIS

TABLE LIST
TABLE 1: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF MERGERS & ACQUISITIONS
TABLE 6: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 7: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2023-2030 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2023-2030 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY END-USER, 2023-2030 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

FIGURE LIST
FIGURE 1: MARKET MATURITY ANALYSIS
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: KEY BUYING IMPACT ANALYSIS
FIGURE 4: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2022 & 2030 (IN %)
FIGURE 5: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY SOFT CELLULITE, 2023-2030 (IN $ MILLION)
FIGURE 6: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY HARD CELLULITE, 2023-2030 (IN $ MILLION)
FIGURE 7: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2022 & 2030 (IN %)
FIGURE 8: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY NON-INVASIVE, 2023-2030 (IN $ MILLION)
FIGURE 9: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY MINIMALLY INVASIVE, 2023-2030 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY TOPICAL, 2023-2030 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY END-USER, 2022 & 2030 (IN %)
FIGURE 12: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY HOSPITALS, 2023-2030 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY CLINICS AND BEAUTY CENTERS, 2023-2030 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY OTHER END-USERS, 2023-2030 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2022 & 2030 (IN %)
FIGURE 16: CHINA CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 17: JAPAN CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 18: INDIA CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 19: SOUTH KOREA CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 20: ASEAN COUNTRIES CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 21: AUSTRALIA & NEW ZEALAND CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 22: REST OF ASIA-PACIFIC CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)

ページTOPに戻る

図表リスト

TABLE LIST
TABLE 1: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF MERGERS & ACQUISITIONS
TABLE 6: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 7: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2023-2030 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2023-2030 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY END-USER, 2023-2030 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)